OpenAI CEO Altman, 39, and Amazon founder Bezos, 60, have shelled out millions in recent years to longevity labs Retro Biosciences and Altos Labs, respectively. PayPal cofounder Thiel, 57, forked over $1 million to the Methuselah Foundation, a biomedical charity that aims to make 90 the new 50 by 2030.

The top billionaires of Silicon Valley have gone from supporting Democrats to being all in on Trump. What happened?

And the timing couldn’t be better, as Donald Trump is set to be inaugurated on Monday. Jeff Bezos, the owner of the Post, will even be in attendance, cheering on his billionaire buddy as America enters a new phase of oligarchy accelerated beyond measure.

NEW YORK, Jan 8: Jeff Bezos, Sam Altman, and Peter Thiel have already conquered the tech world, but now they're investing millions in a new battle: the quest for eternal youth. These tech billionaires are pouring vast sums of their fortunes into the race to extend life, fueling the growth of a $25 billion market for life-extending therapies.

World’s-richest-man Elon Musk, Meta CEO Mark Zuckerberg, and Amazon chief Jeff Bezos are slated to attend the forty-seventh president’s inauguration next week, according to NBC News. The tech trio will be seated alongside elected officials and Trump’s Cabinet selections.

The guest list includes some of America’s most influential tech billionaires and politicians as well as some foreign leaders and celebrities who have embraced Trump.

High-profile tech billionaires, including Jeff Bezos, Mark Zuckerberg and Elon Musk will sit front and center at President-elect Donald Trump's inauguration.

Sam Altman says his researchers still push back in meetings — a positive for him. Altman previously wrote that he was against bureaucracy and supported fostering open communication. Workplace ...

Here's what you need to know this week about artificial intelligence in the Bay Area: Musk pushes for OpenAI auction, Altman sued by sister, Anthropic partially settles lawsuit with music publishers,

A Midtown-based therapeutics company hopes to tap the growing market of anti-aging drugs with a suite of pharmaceutical research, and investors are taking notice. Cambrian Bio recently raised $23 million to advance its portfolio of drug discovery platforms focused on the biological processes that break down with age.

"Jeff Bezos and his cronies accommodate and enable ... Zuckerberg, OpenAI CEO Sam Altman and Los Angeles Times Publisher Patrick Soon-Shiong supplicating before Trump as the president-elect ...